308 related articles for article (PubMed ID: 22901620)
41. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.
Brandalise S; Odone V; Pereira W; Andrea M; Zanichelli M; Aranega V
Leukemia; 1993 Aug; 7 Suppl 2():S142-5. PubMed ID: 8361220
[TBL] [Abstract][Full Text] [Related]
42. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
43. Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Withycombe JS; Post-White JE; Meza JL; Hawks RG; Smith LM; Sacks N; Seibel NL
Pediatr Blood Cancer; 2009 Dec; 53(7):1249-54. PubMed ID: 19688832
[TBL] [Abstract][Full Text] [Related]
44. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
45. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
46. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
47. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Attarbaschi A; Mann G; Zimmermann M; Bader P; Barisone E; Basso G; Biondi A; Cario G; Cazzaniga G; Colombini A; Flotho C; Kuhlen M; Lang P; Lauten M; Linderkamp C; Locatelli F; Lo Nigro L; Möricke A; Niggli F; Panzer-Grümayer R; Parasole R; Peters C; Caterina Putti M; Rizzari C; Suttorp M; Valsecchi MG; Conter V; Schrappe M;
Leukemia; 2020 Jun; 34(6):1694-1700. PubMed ID: 31806872
[No Abstract] [Full Text] [Related]
48. Osteonecrosis in paediatric patients with acute lymphoblastic leukaemia treated on Co-ALL-07-03 trial: a single centre analysis.
Kuhlen M; Moldovan A; Krull K; Meisel R; Borkhardt A
Klin Padiatr; 2014 May; 226(3):154-60. PubMed ID: 24710762
[TBL] [Abstract][Full Text] [Related]
49. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
51. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A; Tallen G; Roumiantseva J; Lagoiko S; Chervova A; von Stackelberg A; Aleinikova O; Bydanov O; Bajdun L; Nasedkina T; Korepanova N; Kuznetsov S; Novichkova G; Goroshkova M; Litvinov D; Myakova N; Ponomareva N; Inyushkina E; Kondratchik K; Abugova J; Fechina L; Arakaev O; Karelin A; Lebedev V; Judina N; Scharapova G; Spichak I; Shamardina A; Ryskal O; Shapochnik A; Rumjanzew A; Boos J; Henze G;
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1001-1012. PubMed ID: 30840197
[TBL] [Abstract][Full Text] [Related]
52. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951.
De Moerloose B; Suciu S; Bertrand Y; Mazingue F; Robert A; Uyttebroeck A; Yakouben K; Ferster A; Margueritte G; Lutz P; Munzer M; Sirvent N; Norton L; Boutard P; Plantaz D; Millot F; Philippet P; Baila L; Benoit Y; Otten J;
Blood; 2010 Jul; 116(1):36-44. PubMed ID: 20407035
[TBL] [Abstract][Full Text] [Related]
53. Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia.
Buendia MT; Terselich G; Lozano JM; Viscaino MP
Med Pediatr Oncol; 1997 Feb; 28(2):108-16. PubMed ID: 8986146
[TBL] [Abstract][Full Text] [Related]
54. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
[TBL] [Abstract][Full Text] [Related]
55. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
56. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
Linker C; Damon L; Ries C; Navarro W
J Clin Oncol; 2002 May; 20(10):2464-71. PubMed ID: 12011123
[TBL] [Abstract][Full Text] [Related]
57. Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).
Hassan IB; Kristensen J; Alizadeh H; Bernsen R
Med Oncol; 2013 Jun; 30(2):519. PubMed ID: 23468219
[TBL] [Abstract][Full Text] [Related]
58. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
Ramanujachar R; Richards S; Hann I; Goldstone A; Mitchell C; Vora A; Rowe J; Webb D
Pediatr Blood Cancer; 2007 Mar; 48(3):254-61. PubMed ID: 16421910
[TBL] [Abstract][Full Text] [Related]
59. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.
Niinimäki RA; Harila-Saari AH; Jartti AE; Seuri RM; Riikonen PV; Pääkkö EL; Möttönen MI; Lanning M
J Clin Oncol; 2007 Apr; 25(12):1498-504. PubMed ID: 17442991
[TBL] [Abstract][Full Text] [Related]
60. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia.
Richards S; Burrett J; Hann I; Chessells J; Hill F; Bailey C
Leukemia; 1998 Jul; 12(7):1031-6. PubMed ID: 9665186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
